TABLE OF CONTENTS

01 From Humble Beginnings
John LaClare - Board Chair .................................................5

02 At the Forefront
Andrew Potter - Director and CEO ........................................6

03 Fostering Innovation
Volker Gerdts - Research .....................................................8

04 Expanding Opportunities
Paul Hodgson - Business Development ..............................11

05 Building Momentum
Cam Ewart - Operations and Maintenance ..........................12

06 It’s a Team Effort
Joyce Sander - Human Resources .....................................15

07 Investing in Growth
Lorne Vanin - Finance .......................................................16
Statement of Financial Position ........................................18
Statement of Operations ...................................................18
Review Statement ............................................................19

08 Community Liaison Committee Report
Susan Lamb - Chair ............................................................19

OUR VISION
Protecting Canada and the world from infectious diseases.

OUR MISSION
To conduct research and develop vaccines and related products, with key national and international partners, for the prevention and control of human and animal disease.

2014-2015 BOARD OF DIRECTORS


2014-2015 Board of Directors: Geographical Representation
Rejean Bouchard – Ontario
Peter Brenders – Ontario
Karen Chad – Saskatchewan
Robert Clarke – Ontario
Alastair Cribb – Alberta
Leonard Edwards – Ontario
Douglas Freeman – Saskatchewan
William Kay – British Columbia
Jerome Konecsni – Saskatchewan
John LaClare (Chair) – Saskatchewan
Terrance Oleksyn – Saskatchewan
Frank Plummer – Ontario
Andrew Potter – Saskatchewan
Craig Vanderwagen – Maryland, USA
“Commercially-focused research has been a hallmark of VIDO-InterVac, resulting in the creation of several world-first vaccines that have greatly impacted the livestock industry. Their trainees have gone on to senior positions in academia, industry and governments around the world, expanding the VIDO-InterVac legacy for years to come.”

Lorne Babiuk (Vice-President Research, University of Alberta and VIDO-InterVac’s 3rd Director)
VIDO-InterVac stands a testament to the vision and commitment of not only those that contributed to the organization’s creation in 1975, but to all those who have followed. To all of those who have turned dreams into reality, who have brought their knowledge, skills and financial support to solve some of the most perplexing issues facing both animal and human health. Early in my career I listened to livestock industry leaders speak to the importance of VIDO and its work. If only they could have imagined the VIDO-InterVac of today, its impact on human and animal health, its facilities and most importantly its personnel.

VIDO-InterVac is proud of its humble beginnings in 1975 which set the stage for the organization’s ongoing success. In 1978, VIDO launched its first vaccine “VICOGEN,” a vaccine for calf scours, in collaboration with Connaught Laboratories. This was a game changer for the livestock sector: calving season was transformed from a time of struggle to one of fulfillment. The growth continued with: additional vaccines commercialized; start-up companies created; employment growth for the province as staffing increased; broadened research goals to include human infectious diseases; the opening of a research station and major containment level 2 and 3 expansions; and ISO 9001 certification. The accomplishments continue.

In 2015, we celebrate VIDO-InterVac’s 40-year history. It has continued to advance science to the betterment of both human and animal populations. It has distinguished itself as a world leader in both vaccines and delivery platforms. As with those that have come before us, we can only imagine VIDO-InterVac 40 years from now, its successes far outpacing what we currently envision as possible.

Indeed, VIDO-InterVac’s success has been the result of its depth of talent, inspired leadership, sage counsel and mutually-beneficial partnerships. It has and will continue to be a collective effort. On behalf of the Board of Directors I would like to acknowledge the entire VIDO-InterVac team for their efforts, enthusiasm and commitment.

Respectfully,

John LaClare - Board Chair
This year represents a significant milestone for VIDO-InterVac, its 40th anniversary as a research enterprise. I have had the honour and pleasure of witnessing the growth and achievements of the organization for 30 of its 40 years. It has been truly amazing to see the original vision of Dr. Christopher Bigland transform from the Veterinary Infectious Disease Organization to the Vaccine and Infectious Disease Organization and more recently to the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac). From the original ATCO trailers to the incredible infrastructure we work in today, VIDO-InterVac personnel and partners have developed a total of eight commercially-available vaccines, six of which were the first of their kind, illustrating the importance of the individuals who have made their careers here. These vaccines were truly innovative and have stood the test of time in terms of their effectiveness.

VIDO was founded through a partnership of the four western Provinces and this remains to this day. We have successfully forged new public and private partnerships at both national and international levels, in part due to our original funding model. These have served as a foundation for the enduring collaborative and team-based culture present in the organization and remain important to this day. Zoonotic diseases and the global movement of pathogens has also been in the public eye more than ever and therefore our international activities have expanded significantly, particularly in central and east Asia. The opening of the InterVac containment facility has facilitated this expansion of our activities significantly, since virtually all emerging diseases require the use of a containment level 3 facility.

VIDO-InterVac’s original mandate was to work in the animal health field and it has done remarkably well in this area. However, the convergence of human and animal health over the past 25 years and the applicability of veterinary technologies to the human health sector has served as a springboard for VIDO-InterVac to work in both areas. Our work in large animals has served as a strength in the “de-risking” of human vaccine technologies such as vaccines for Respiratory Syncytial Virus in which we use both sheep and cattle models. Likewise, our work on bovine tuberculosis and Johne’s Disease are expected to provide insights into human tuberculosis infection, a disease for which vaccine solutions have been evasive at best. We continue to be at the forefront of infectious disease research, and during 2014-2015 we witnessed the entry of Porcine Epidemic Diarrhea virus into Canada. Due to the foresight of Dr. Gerdts and his colleagues, we were able to initiate studies on the development of a vaccine before the first case in Canada was diagnosed. We now have a prototype vaccine which will enter field trials in the very near future once regulatory approval has been obtained.

In summary, the past 40 years have been exciting and productive ones for VIDO-InterVac, and our success has been due to our team, our Board of Directors, stakeholders in both public and private sectors and our funders. We look forward to the challenges of the future and I am confident that the organization will continue to be a global leader in the fight against infectious disease.

Andrew Potter (Director and CEO of VIDO-InterVac)
THE NUMBER OF COMMERCIAL VACCINES DEVELOPED BY VIDO-INTERVAC PERSONNEL AND PARTNERS SINCE 1975
40 years of successful research by our staff, partners and collaborators has resulted in tremendous benefit to the health of Canadians and their livestock, and health and welfare globally. Eight of our vaccines for livestock were successfully commercialized and several others are currently in preclinical and clinical development. Multiple technologies were licensed to industry, including novel adjuvants and platforms for vaccine production and delivery that are protected by more than 100 U.S. patents. Additionally, in excess of a thousand highly qualified individuals have been trained at VIDO-InterVac and are now part of an impressive network of alumni, with many in senior positions of government, industry and academia.

The last year has brought a number of exciting scientific opportunities to the organization. In 2013, the Porcine Epidemic Diarrhea virus (PEDV) was first reported in North America, and within 12 months the disease had killed more than 7 million pigs in the U.S. alone. While Canada has experienced fewer outbreaks, PEDV remains a significant threat to the Canadian swine industry and substantial resources are being spent to contain outbreaks. In late 2013, before the first disease was diagnosed in Canada, we initiated the development of a vaccine for PEDV, illustrating our ability to respond rapidly to emerging threats. In less than 18 months we successfully developed a vaccine candidate and produced several thousand doses for further testing in commercial herds. It is our goal to make this vaccine available to producers in the very near future. Another example of an emerging threat to human and animal health is influenza. With support from the Public Health Agency of Canada, scientists at VIDO-InterVac are developing strategies to combat novel highly pathogenic influenza strains and other emerging diseases.

In partnership with the Pan-Provincial Vaccine Enterprise (PREVENT), VIDO-InterVac is currently developing the world’s first vaccine for a protein misfolding disease. Chronic Wasting Disease is a transmissible spongiform encephalopathy of deer and elk, with catastrophic consequences to captive and free-ranging cervid populations in North America. A novel vaccine candidate was recently developed at VIDO-InterVac and, after successful preclinical testing, a large clinical trial in elk was started 12 months ago using our containment level 3 facility.

Another example of a late-stage vaccine candidate is our vaccine for respiratory syncytial virus, a serious disease of young children and infants. A prototype vaccine was developed and tested successfully in preclinical trials. In partnership with PREVENT, Dalton Pharmaceuticals, the South China United Vaccine Institute and the Guangzhou Institute of Respiratory Disease, the vaccine is being improved by including antigens for the parainfluenza type 3 virus. Both viruses cause serious diseases in children around the world, and no vaccines are currently available.

“As a producer, VIDO-InterVac gives me hope that future threats to the health of my beef cattle are being actively researched and that solutions to manage these disease events, if they should occur on my ranch, are being created.”

Terry Oleksyn (Beef Producer and member of the VIDO-InterVac Board of Directors)
Lastly, we have made significant progress developing a vaccine for an important cattle disease of Sub-Saharan Africa. Contagious bovine pleuropneumoniae (lung plague) is caused by *Mycoplasma mycoides* and is responsible for significant socioeconomic problems for small-scale farmers. This project, funded by the International Development Research Centre and Foreign Affairs, Trade and Development Canada, and in collaboration with the Kenya Agriculture and Livestock Research Organization and the International Livestock Research Institute in Kenya, used reverse vaccinology to develop a novel subunit vaccine shown to be effective in preclinical trials. Efforts are now focused on establishing vaccine production with the Kenya Veterinary Vaccines Production Institute and field-testing the vaccine candidate in African countries. Other examples of our research can be accessed via our website.

As VIDO-InterVac grows we will continue to focus on the development of our scientific team. We have been successful in recruiting two new scientists within the last 12 months: Dr. Jeffrey Chen and Dr. Darryl Falzarano. Dr. Chen, an expert in Mycobacterial diseases including human tuberculosis, was hired to strengthen our tuberculosis research. Dr. Falzarano, an expert in emerging viral infections, was hired to strengthen our effort to address and prepare for emerging viral infections, such as the Middle-Eastern Respiratory Syndrome currently affecting several countries in Southern Asia. We look forward to their contributions to our success in the coming years.
“Our partnership with VIDO-InterVac and the use of cutting-edge livestock vaccine research is solving food security problems that impact on the lives of the poor. These interventions have the potential to improve their livelihoods towards a brighter tomorrow.”

Arshad Mather (Agricultural Research Council- Onderstepoort Veterinary Institute in South Africa)
2015 marks four decades of growth and impact for our organization. During that time, we have partnered with industry to commercialize eight vaccines, have been instrumental in the establishment of several spinoff companies, and developed strong partnerships with academia, government and industry to advance human and animal infectious disease research. Despite these accomplishments, recent worldwide events including a swine coronavirus reaching North America, measles outbreaks, the spread of the MERS, and the largest Ebola outbreak in history demonstrate the continued challenge that infectious diseases present to human and animal health. Fortunately, strategic foresight has provided our organization with the infrastructure and expertise required to play an international role in meeting the emerging and re-emerging infectious disease threats of the future.

During the past year, our organization continued to expand our network of strategic partnerships to advance global vaccine development. As examples, we have aligned efforts with the Government of Canada’s Public Health Agency to aid in the achievement of national priorities, signed formal agreements worth millions of dollars with industry and government in Asia, Africa and Europe, and expanded our involvement with the human and animal health industries by offering technology commercialization opportunities and providing research services.

A key strategic goal of the organization is enhancement of communication activity with stakeholders. During the past year, we hosted Ambassadors and high commissioners from over 30 countries, increased engagement with industry partners, hosted Canada’s Vaccine Industry Committee’s first meeting held in Western Canada, and enabled hundreds of students to experience benchtop science through events like the Gairdner lecture series. Our online communication was also enhanced by the redevelopment of our website and participation with social media. These activities are building our brand and reputation locally, nationally and internationally.

As we celebrate this organizational milestone, VIDO-InterVac remains committed to achieving our strategic goals. We are driven to meet the needs of our partners, engage in effective communication and develop the targeted technology required to protect Canada and the world from infectious disease.
“VIDO-InterVac has demonstrated that with a focus on excellence in research, a willingness to collaborate and a vision to provide novel health solutions for the animal industry, you can be a world class research organization no matter where you are located.”

Brad Wildeman (President, Pound-Maker Agventures Ltd.)

As our founding Director, Dr. Bigland, stated in VIDO’s inaugural annual report, a main organizational goal was to develop infrastructure that was “unique in Canada and scarce in the world.” Over the past 40 years, we continually invested in laboratories and animal housing not found elsewhere for the research of infectious disease. With each subsequent expansion, VIDO-InterVac became better equipped to advance infectious disease research and support scientific innovation. To highlight several:

- 1978 – we opened our first permanent laboratory and animal housing
- 1987 – operation began at the 160 acre research station for large animal trials
- 2003 – we opened our 50,000 square foot containment level 2 laboratory expansion
- 2013 – certification was received for the International Vaccine Centre, a containment level 3 laboratory and animal housing facility

VIDO-InterVac’s operations and maintenance team is proud of our buildings, our work and our contribution toward ensuring that the research and development occurring within our organization can succeed. As part of this effort, we continue to fine tune InterVac’s operation so that this high containment facility functions in the safest manner possible, while maximizing available resources.

VIDO-InterVac’s infrastructure is a reflection of the importance of the work that has occurred, and continues to occur within the organization. As we begin our fifth decade, we look forward to the opportunities that these buildings will provide, and welcome the challenge of maintaining them to the highest degree of efficiency.
200K
THE AMOUNT OF SQUARE FOOTAGE VIDO-INTERVAC HAS EXPANDED SINCE INCEPTION
“I had the pleasure of completing my graduate education within the world-class laboratories at VIDO-InterVac. This experience provided me with the opportunity to further study high-consequence pathogens, and led me to be the scientific lead for an Ebola diagnostic laboratory in Liberia.”

Jason Kindrachuk (Staff Scientist at the National Institutes of Health)
When asked why VIDO-InterVac is successful, the answer is simple: It’s our team.

Our 40th anniversary is a great opportunity to say thank you to our staff for their commitment and passion. Taking care of our workforce and enabling them to strive to achieve our vision has been the key to our success. VIDO-InterVac has never been stronger and we remain engaged in research projects that are key to mitigating the threats of future disease.

Our 40-year journey has seen a great deal of success. To highlight a few:

- Teams have worked together to improve human and animal health resulting in commercialized vaccines
- Our excellent training environment has developed highly qualified personnel that are leaders in academia, government and industry
- We have partners on five continents and a multicultural staff representing more than 20 nations
- Our ISO 9001 certification is an excellent example of our employees’ commitment to deliver quality science to our partners

As VIDO-InterVac enters the next chapter in its history, we will actively seek more opportunities to improve health across the globe. We are well-positioned for continued innovation and success for years to come.
VIDO-InterVac’s tremendous growth in the pursuit of scientific excellence has meant significant financial activity. 40 years ago VIDO was established with revenue of $200,000 a year. Our revenue is now over $18 million and it comes from a wide variety of sources, including federal and provincial governments, producer groups and agencies, foundations and companies (see graph on next page). We are financially accountable to these organizations and continue to meet their reporting requirements to ensuring that all funding is managed appropriately.

Since the opening of our containment level 3 facility, revenue has grown substantially. Revenue increased by 12% in 2014-2015. This was due to a combination of increased contract research, grants, and additional funding from the University of Saskatchewan and Government of Saskatchewan. Equity increased by over $2 million dollars in 2014-2015 helping to ensure the continued activities of the organization. We were also awarded funding from a variety of sources for innovative research projects including our first grant from the Government of Canada’s Public Health Agency, a second grant for continued vaccine development in Africa, and funding from ISTP Canada and CIHR in collaboration with partners in China.

In order to meet our strategic operational objectives and ensure operational sustainability, we continue to pursue funding from a variety of sources and focus on the effective management of expenses. Over the past year expenses grew by 10% primarily due to increases in research activity. These continuous investments into our research, team and facility will ensure VIDO-InterVac remains successful in the years to come.

The Finance Department supports the management of the organization to ensure the future success of VIDO-InterVac. As we celebrate 40 years of amazing growth, we thank our contributors and look forward to continued relationships in the years to come.

“Training at VIDO-InterVac helped prepare me for a smooth transition from academia to industry. Their guidance continues to play a role in my endeavors.”

Sanjeev Anand (Research Scientist, Elanco)
1975–2015 REVENUE

$ 20,000,000
$ 15,000,000
$ 10,000,000
$ 5,000,000
$ 0


* REPORTING PERIOD CHANGED

2014–2015 REVENUE SOURCES

GOVERNMENT OF CANADA OPERATING 18%

GOVERNMENT OF SASKATCHEWAN OPERATING 39%

CONDITIONAL GRANTS 23%

UNIVERSITY OF SASKATCHEWAN 9%

COMMERCIAL 8%

OTHER 3%

$200K
VIDO–INTERVAC’S REVENUE IN 1975

$18M
VIDO–INTERVAC’S REVENUE IN 2015
## UNIVERSITY OF SASKATCHEWAN
VACCINE AND INFECTIOUS DISEASE ORGANIZATION-INTERNATIONAL VACCINE CENTRE

### STATEMENT OF FINANCIAL POSITION

AS AT APRIL 30, 2015

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funds Held - University of Saskatchewan</td>
<td>$15,381,523</td>
<td>$17,549,709</td>
</tr>
<tr>
<td>Accounts Receivable</td>
<td>3,613,849</td>
<td>6,632,205</td>
</tr>
<tr>
<td>Inventories</td>
<td>128,677</td>
<td>175,250</td>
</tr>
<tr>
<td></td>
<td>19,124,049</td>
<td>24,357,164</td>
</tr>
<tr>
<td><strong>LONG TERM ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long Term Accounts Receivable</td>
<td>342,374</td>
<td>369,896</td>
</tr>
<tr>
<td>Investments</td>
<td>12,549,993</td>
<td>12,184,886</td>
</tr>
<tr>
<td>Capital Assets</td>
<td>14,521,218</td>
<td>14,988,105</td>
</tr>
<tr>
<td></td>
<td>46,537,634</td>
<td>51,900,051</td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts Payable</td>
<td>$205,333</td>
<td>$451,765</td>
</tr>
<tr>
<td>Accrued Vacation Pay</td>
<td>727,559</td>
<td>735,254</td>
</tr>
<tr>
<td></td>
<td>932,892</td>
<td>1,187,019</td>
</tr>
<tr>
<td><strong>UNEARNED REVENUE</strong></td>
<td>12,149,933</td>
<td>19,468,737</td>
</tr>
<tr>
<td></td>
<td>13,082,825</td>
<td>20,655,756</td>
</tr>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTERNALLY RESTRICTED FUNDS</td>
<td>18,933,591</td>
<td>16,256,190</td>
</tr>
<tr>
<td>INVESTMENT IN CAPITAL ASSETS</td>
<td>14,521,218</td>
<td>14,988,105</td>
</tr>
<tr>
<td></td>
<td>33,454,809</td>
<td>31,244,295</td>
</tr>
<tr>
<td></td>
<td>46,537,634</td>
<td>51,900,051</td>
</tr>
</tbody>
</table>

Unaudited

### UNIVERSITY OF SASKATCHEWAN
VACCINE AND INFECTIOUS DISEASE ORGANIZATION-INTERNATIONAL VACCINE CENTRE

### STATEMENT OF OPERATIONS

FOR THE YEAR ENDED APRIL 30, 2015

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INCOME</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Government of Canada Operating</td>
<td>$3,467,437</td>
<td>$2,922,567</td>
</tr>
<tr>
<td>Government of Saskatchewan Operating</td>
<td>7,437,548</td>
<td>6,495,293</td>
</tr>
<tr>
<td>Conditional Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Government of Canada Research</td>
<td>1,303,721</td>
<td>1,682,035</td>
</tr>
<tr>
<td>Government of Saskatchewan Research</td>
<td>1,593,891</td>
<td>1,774,004</td>
</tr>
<tr>
<td>Other Governments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unconditional Revenue</td>
<td></td>
<td>16,200</td>
</tr>
<tr>
<td>University of Saskatchewan</td>
<td>1,681,621</td>
<td>1,230,038</td>
</tr>
<tr>
<td>Miscellaneous Income</td>
<td>50,512</td>
<td>15,692</td>
</tr>
<tr>
<td>Gain (Loss) on Disposal of Capital Assets</td>
<td>4,263</td>
<td>4,263</td>
</tr>
<tr>
<td></td>
<td>18,825,795</td>
<td>16,777,322</td>
</tr>
<tr>
<td><strong>EXPENDITURE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salaries and Benefits</td>
<td>8,637,545</td>
<td>7,922,168</td>
</tr>
<tr>
<td>Materials and Supplies</td>
<td>3,213,276</td>
<td>2,845,684</td>
</tr>
<tr>
<td>Maintenance</td>
<td>1,233,200</td>
<td>959,600</td>
</tr>
<tr>
<td>Utilities</td>
<td>982,871</td>
<td>990,927</td>
</tr>
<tr>
<td>Sub-contract Research</td>
<td>584,114</td>
<td>520,768</td>
</tr>
<tr>
<td>Travel and Recruiting</td>
<td>443,201</td>
<td>487,564</td>
</tr>
<tr>
<td>Patents and Legal Fees</td>
<td>182,222</td>
<td>90,535</td>
</tr>
<tr>
<td>Amortization</td>
<td>1,298,189</td>
<td>1,216,701</td>
</tr>
<tr>
<td>Other Expenditures</td>
<td>40,662</td>
<td>102,601</td>
</tr>
<tr>
<td></td>
<td>16,615,281</td>
<td>15,136,548</td>
</tr>
<tr>
<td><strong>EXCESS OF INCOME OVER EXPENDITURE</strong></td>
<td>2,210,514</td>
<td>1,640,774</td>
</tr>
<tr>
<td><strong>FUND BALANCES, BEGINNING OF YEAR</strong></td>
<td>31,244,295</td>
<td>29,603,521</td>
</tr>
<tr>
<td><strong>FUND BALANCES, END OF YEAR</strong></td>
<td>33,454,809</td>
<td>31,244,295</td>
</tr>
<tr>
<td>INTERNALLY RESTRICTED FUNDS</td>
<td>18,933,591</td>
<td>16,256,190</td>
</tr>
<tr>
<td>INVESTMENT IN CAPITAL ASSETS</td>
<td>14,521,218</td>
<td>14,988,105</td>
</tr>
<tr>
<td></td>
<td>33,454,809</td>
<td>31,244,295</td>
</tr>
</tbody>
</table>

Unaudited
The Community Liaison Committee (CLC) is an example of best practices for biocontainment facilities worldwide. Made up of community leaders, the role of the independent CLC is to provide information to the public regarding safety and security at VIDO’s containment level 3 facility InterVac. The goal is to create and maintain an atmosphere of public trust and confidence between InterVac and the local and national communities. The committee has been given the mandate to be informed of InterVac activities when they become of public interest. The committee meets regularly to be briefed on the work at InterVac.

The CLC is committed to staying current on issues relating to infectious disease, particularly as they apply to VIDO-InterVac. It holds an annual meeting to give the public an opportunity to ask questions in an effort to maintain public confidence in VIDO-InterVac’s operations.

Community members may contact the committee at (306) 270-1729.

COMMUNITY LIAISON COMMITTEE REPORT
SUSAN LAMB - CHAIR

The University of Saskatchewan’s Financial Reporting Department has examined the Financial Statements as prepared by VIDO-InterVac and has found that the figures presented therein reconcile to the University’s financial records. In addition, Financial Reporting has reviewed the adjusting transactions and has concluded that the adjustments are reasonable and accurate. Therefore, the University of Saskatchewan can confirm that the statements as presented by VIDO-InterVac are accurate and in accordance with the University’s financial policies.

Financial statement users are cautioned that these statements have not been audited or reviewed for purposes other than those described above.

Dustin Bertsch, CA
Financial Analyst, Financial Reporting
Financial Services Division, University of Saskatchewan

/review-statement-August-27-2015/

THE PERCENTAGE OF GROWTH IN VIDO-INTERVAC’S REVENUE IN 2014-2015 AS COMPARED TO THE PREVIOUS FISCAL YEAR
Abcelex Technologies Inc.
Akshaya Bio Inc.
Alberta Egg Producers
Alberta Livestock and Meat Agency
Alberta Milk
Aquila Diagnostic Systems Inc.
Boehringer Ingelheim Vetmedica Inc.
Bovicor Pharmatech Inc.
Canadian Cattlemen’s Association
Canadian Institute of Health Research
Canadian Poultry Research Council
Chicken Farmers of Saskatchewan
Danone Research
Elanco
Genome Alberta
Genome British Columbia
Genome Prairie
GlaxoSmithKline Biologicals SA
Government of Canada
Government of Manitoba
Government of Ontario
Government of Saskatchewan
Grand Challenges Canada
Intervet Inc.
Jarislowsky Chair in Biotechnology
Kamloops Stockmen’s Association
Krembil Foundation
Meadow Ridge Enterprises
Merck Animal Health
Merial
National Pork Board
Natural Sciences & Engineering Research Council of Canada
Novartis Animal Health
Ontario Pork
Pan-Provincial Vaccine Enterprise Inc.
Pfizer Canada Inc.
Prevtec Microbia Inc.
Public Health Agency of Canada
Qatar University
Saskatchewan Health Research Foundation
Texas A & M University
The Banting Research Foundation
University of Alberta
University of Calgary
Zoetis LLC

VIDO-InterVac
Vaccine and Infectious Disease Organization - International Vaccine Centre

University of Saskatchewan

Vaccine and Infectious Disease Organization - International Vaccine Centre • 120 Veterinary Road • Saskatoon, SK • Canada • S7N 5E3 • www.vido.org